---
title: "FDA nimmt Zulassungsantrag für Oveporexton von Takeda zur Prüfung an"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275421640.md"
description: "The FDA has accepted Takeda Pharmaceutical Co. Ltd.'s application for Oveporexton (TAK-861) to treat Type 1 Narcolepsy and granted it Priority Review. The decision deadline under the Prescription Drug User Fee Act (PDUFA) is set for the third quarter of this calendar year."
datetime: "2026-02-10T08:01:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275421640.md)
  - [en](https://longbridge.com/en/news/275421640.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275421640.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275421640.md) | [繁體中文](https://longbridge.com/zh-HK/news/275421640.md)


# FDA nimmt Zulassungsantrag für Oveporexton von Takeda zur Prüfung an

Die US-Arzneimittelbehörde FDA hat den Zulassungsantrag für Oveporexton (TAK-861) von Takeda Pharmaceutical Co. Ltd. zur Behandlung von Narkolepsie Typ 1 angenommen und ein beschleunigtes Prüfverfahren (Priority Review) gewährt. Der Zieltermin für die Entscheidung im Rahmen des Prescription Drug User Fee Act (PDUFA) liegt im dritten Quartal dieses Kalenderjahres. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Takeda Pharmaceutical Co. Ltd. (4502.JP)](https://longbridge.com/en/quote/4502.JP.md)
- [Takeda Pharmaceutical Company Limited (TAK.US)](https://longbridge.com/en/quote/TAK.US.md)

## Related News & Research

- [Takeda Pharmaceutical to Cut 400 US Jobs, Invest in Blood Products](https://longbridge.com/en/news/277827484.md)
- [How FDA Priority Review For Narcolepsy Drug Oveporexton At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story](https://longbridge.com/en/news/276281923.md)
- [Yokogawa Electric Corp - cancellation of common stock](https://longbridge.com/en/news/277572286.md)
- [Takeda, Protagonist Say FDA Accepts New Drug Application for Potential Polycythemia Vera Treatment](https://longbridge.com/en/news/277429641.md)
- [FDA Accepts Takeda's Oveporexton Application for Priority Review in Narcolepsy Type 1](https://longbridge.com/en/news/275421654.md)